Sandoz Settlement Sets Date For US Denosumab Entry
Deal With Amgen Ends Litigation, Allowing Prolia/Xgeva Biosimilars To Launch Next Year
Sandoz has secured a launch date for its newly-approved US denosumab biosimilars, settling patent litigation with Prolia/Xgeva originator Amgen.
